Saturday, March 25, 2017

DEA approves synthetic marijuana for big pharma company against legalization

A synthetic marijuana product could be available for
commercialization after the DEA gave a newly approved drug a schedule II
classification.

On Thursday, Insys Therapeutics announced
that the Drug Enforcement Administration (DEA) issued an interim final
rule that would put Syndros, their synthetic marijuana drug, on Schedule
II of the Controlled Substances Act (CSA).

“Insys is looking
forward to bringing this new drug product to chemotherapy patients to
help alleviate their nausea and vomiting and AIDS patients with anorexia
associated weight loss, respectively,” Dr. Santosh Vetticaden, interim CEO, said in the announcement.

“We
look forward to interacting with the FDA to finalize the labeling and
subsequent launch of Syndros in the second half of 2017,” Vetticaden said.

Syndros is a synthetic version of tetrahydrocannabinol (THC), the
main psychoactive component in the plant. In July 206, the company announced
the FDA approved their liquid form of synthetic THC to treat anorexia
associated AIDS patients, and nausea and vomiting induced by cancer
patients going through chemotherapy.

The DEA approval placed Syndros and its generic formulations in schedule II of the CSA, which is reserved for drugs that have “a high potential for abuse, with use potentially leading to severe psychological or physical dependence.”

While
some Schedule II drugs can be used for medical purposes, like Vicodin,
oxycodone, Adderall, and many prescription painkillers, Schedule I drugs
are all federally illegal. Non-synthetic marijuana is a Schedule I
drug, which is reserved for drugs that have “no currently accepted medical use and a high potential for abuse.”

In 2011, Insys wrote a letter to the DEA, urging them to maintain the Schedule I status for non-synthetic marijuana, citing “a
longstanding policy of the United States to disfavor domestic
cultivation of narcotic raw materials because of concerns about the
abuse potential from farming of this material."

Insys also
opposed legalization in Arizona, donating $500,000 to Arizonans for
Responsible Drug Policy, a group opposing Proposition 205, an initiative
to legalize and regulate marijuana like alcohol in Arizona.

In a statement, Insys said it opposed Prop 205, "because it fails to protect the safety of Arizona’s citizens, and particularly its children,” according to the Arizona Republic.

The proposition was narrowly defeated in the state, meaning users in
Arizona could face felony charges for possessing even small amounts of
the plant.

JP Holyoak, chairman of the Campaign to Regulate Marijuana Like Alcohol in Arizona, says Insys funded the opposition “to kill a non-pharmaceutical market for marijuana in order to line their own pockets,” according to the Washington Post.

In 2007, Insys filed a disclosure statement with the Securities and Exchange Commission, directly stating that marijuana legalization would threaten their products.

“If
marijuana or non-synthetic cannabinoids were legalized in the United
States, the market for dronabinol product sales would likely be
significantly reduced and our ability to generate revenue and our
business prospects would be materially adversely affected,” the company said.

The
company is currently under investigation for illegally marketing
Fentanyl, an opioid that is 50 times stronger than heroin, which has
been linked to the death of Prince last year.

In December, several executives at the company were arrested
and the CEO was forced to step down after they were charged with using
speakers fees to entice doctors to prescribe Subsys, a medication for
cancer patients that contains Fentanyl.

"You have a company
using profits from the sale of what has been called 'the most potent and
dangerous opioid on the market’ to prevent adults from using a far less
harmful substance," Holyoak said according to the Arizona Republic.